Many individuals with autism experience symptoms of inattention, hyperactivity, and emotional reactivity—but most current treatments rely on stimulants or sedating antipsychotics, which can create tradeoffs in personality, appetite, or mood.
RT8412 was designed to address these challenges without those side effects. By targeting neuronal pathways, neuroinflammation, and oxidative stress, it aims to improve focus, emotional control, and impulse regulation—especially in children and adults with overlapping ADHD traits.
RT8412 is a synthetic small molecule designed to reduce neuroinflammation, oxidative stress, and neurotransmitter dysfunction—three biological factors strongly linked to ADHD symptoms. It offers a new, non-stimulant approach to improving attention, focus, and working memory by modulating key signaling pathways without directly activating them. This mechanism is intended to support cognitive performance while avoiding the side effects often associated with stimulant-based treatments.
RT8412 is designed to improve attention, regulation, and behavior in autism without relying on stimulants or sedation—offering a more targeted, better tolerated path to functional gains.
RT8412 was developed for the ADHD-like phenotype seen in many individuals with autism—marked by inattention, hyperactivity, and emotional reactivity. But the biology it targets extends far beyond that subgroup.
By modulating neuronal signaling and reducing brain inflammation, RT8412 is well positioned to expand into broader ADHD populations, including children and adults. Its non-stimulant design also makes it a compelling candidate for anxiety, executive dysfunction, and impulse-control disorders where overstimulation is a concern.
